stockrowOvid Therapeutics
OVID Healthcare Biotechnology
Ovid Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $7.3 million, up 1,181.3% from fiscal 2024.
- Revenue
- +463.9%
- EPS
- −33.3%
- Free cash flow
- −268.5%
- Total debt
- −11.7%
Quarter to June 2026, against a year earlier
Follow OVID
Alert me
Ovid Therapeutics (OVID) EV/Sales
As of 6 November 2026, Ovid Therapeutics (OVID) trades at a EV/Sales of 58.7×. Over the past ten years it has ranged from −55.5× (June 2024) to 1,002× (September 2023); the current reading is higher than 87% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.6× | (81.43%) |
| FY2024 | 46.4× | (87.29%) |
| FY2023 | 365× | 324,440.50% |
| FY2022 | 0.1× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 54.1× | 527.64% |
| Dec 2025 | 8.6× | (28.03%) |
| Sep 2025 | 12.0× | — |
| Jun 2025 | −0.3× | — |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NGNE Neurogene Inc. compare | n/m |
| FTH Faeth Therapeutics, Inc. compare | n/m |
| SLBT SL SCIENCE HLDG compare | n/m |
| CLYM Climb Bio, Inc. compare | n/m |
| PBYI Puma Biotechnology, Inc. compare | 1.5× |
| CAPR Capricor Therapeutics, Inc. compare | 13.5× |
| OVID Ovid Therapeutics | 58.7× |
| ENTX Entera Bio Ltd. compare | 643× |
| YDES YD Bio Limited compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)